Saint-Gobain Acquires Three Construction Chemical Firms

Saint-Gobain has strengthened its construction chemicals business with the acquisition of three companies: Interstar Materials in North America, Isoltech in Italy, and Soquimic in Peru.

Saint-Gobain logo on a building
© Sophie Animes - stock.adobe.com

Interstar, operating from facilities in Canada and the US, supplies high-performance pigments for concrete, expanding Saint-Gobain’s decorative and architectural concrete solutions portfolio.

Based in northern Italy, Isoltech develops additives for cellular concrete, a lightweight material valued for its insulation, fire resistance, and recyclability, supporting sustainable building practices.

Soquimic, with two plants near Lima and Arequipa, enhances Saint-Gobain’s reach in the high-growth Peruvian market while complementing its existing local operations.

Collectively, these acquisitions will generate around €25 million in additional annual revenue and will benefit from Chryso’s expertise in innovation, R&D, and low-carbon solutions. They align with Saint-Gobain’s “Grow & Impact” strategy, reinforcing its global leadership and accelerating the development of advanced, sustainable construction products tailored to evolving market needs.

Company

Logo:

Saint-Gobain

Tour Saint-Gobain - 12 place de l’Iris
92096 La Défense Cedex
France

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.